Histopathological analysis of infiltrating T cell subsets in acute T cell-mediated rejection in the kidney transplant

Table 1 Baseline clinical and demographic characteristics of the kidney transplant patients

Characteristic	n3	No rejection	n4	ATCMR	P value
Age (yr)1	7	60.8	14	44.9	0.0101
Male sex (%)	7	57.14	14	71.43	0.6384
Race Chinese (%)	7	86.71	14	57.14	0.3371
Dialysis vintage (yr)1	7	2.08	14	5.015	0.6888
Transplant vintage (yr)1	7	13.75	14	3.935	0.0031
Deceased donor (%)	6	66.67	13	53.85	> 0.9999
Delayed graft function (%)	6	33.33	12	41.67	> 0.9999
Cold ischaemia time (h)	5	3	9	10	0.6973
Total HLA mismatch (#)1	6	3	11	3	0.9973
Very high immune risk (%)2	6	16.67	11	43.45	0.3334
% Panel of reactive antibodies1	3	8	9	0	0.2318
History of ATCMR (%)	7	14.29	14	50	0.1736
Re-transplant (%)	7	0	14	7.14	> 0.9999
GFR at biopsy (mL/min per 1.73 m2)1	7	41.2	14	17.95	0.0767
Proteinuria at biopsy (g/d)1	7	3.5	14	1.23	0.2028
t score1	7	0	14	2	0.0116
I score1	7	1	14	2	0.0007
v score1	7	0	14	0	0.1196
Tacrolimus use at biopsy (%)	7	0	14	50	0.0468
Ciclosporin use at biopsy (%)	7	100	14	35.71	0.0071
MTORI use at biopsy (%)	7	0	14	14.29	0.5333
Steroids use at biopsy (%)	7	100	14	100	> 0.9999
Mycophenolate use at biopsy (%)	7	57.14	14	85.71	0.28
Azathioprine use at biopsy (%)	7	28.57	14	0	0.10
Anti-CD25 induction (%)	5	0	12	41.67	0.2445
Prior thymoglobulin use (%)	7	14.29	14	14.29	> 0.9999

¹Results reported as median values;

²According to United Kingdom Fuggle’s classification based on HLA-DRB1 and HLA-B mismatches[30];

³Indicates the number of patients with available data in the non-rejection group;

⁴Indicates the number of patients with available data in the ATCMR-KTx group. ATCMR: Acute T cell-mediated rejection; GFR: Glomerular filtration rate; HLA: Human leukocyte antigen; MTORI: Mammalian target of rapamycin inhibitor.